Single Dose Intranasal Oxytocin and Cognitive Effects in Autism
Single Dose Intranasal Oxytocin (IN-OT) Versus Placebo in Autism: Examining Cognitive Effects
Sponsor: University of Minnesota
This PHASE2 trial investigates Autism Spectrum Disorders and is currently completed. University of Minnesota leads this study, which shows 11 recorded versions since 2014 — indicating substantial longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2022 — Feb 2023 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE2
▶ Show 6 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Nov 2019 — Feb 2020 [monthly]
Recruiting PHASE2
-
Mar 2019 — Nov 2019 [monthly]
Recruiting PHASE2
Status: Completed → Recruiting
-
Jun 2018 — Mar 2019 [monthly]
Completed PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
May 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- University of Minnesota
For direct contact, visit the study record on ClinicalTrials.gov .